What the Experts Say

There are hundreds of clinical trials and reports published, proving the efficacy of CBT-i in the treatment of insomnia. The general finding is that CBT-i is the only cure for insomnia and should be the first line of treatment. It is found to have a 70% success rate (a very high outcome figure in medical terms) and long-term effect.

Below are some examples of publications about its efficacy:

European Insomnia Guideline

The European Insomnia Guideline, published in 2017, recommends CBTi as “the first line treatment for chronic insomnia in adults of any age (strong recommendation; high quality evidence)”. This European guideline for the diagnosis and treatment of insomnia was developed by a task force of the European Sleep Research Society, with the aim of providing clinical recommendations for the management of adult patients with insomnia. The guideline is based on a systematic review of relevant meta-analyses published till June 2016.

The British Association of Psychopharmacology

The British Association of Psychopharmacology found that CBTi is an effective treatment with long-term benefits.

The American College of Physicians

The American College of Physicians “recommends that all adult patients receive cognitive behavioural therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder.”

N.I.C.E.

The National Institute for Health and Care Excellence (N.I.C.E.) recommend CBTi for long-term insomnia sufferers.

CBTi report in 2015

The European Sleep Research Society and the American Academy of Sleep Medicine both support CBTi as the first line of treatment for insomnia. The American Medical Association published a report in 2015 on the efficacy of CBTi

CBTi report in 2017

A 2017 report published by the Centre for Sleep Medicine found that “CBTi is more effective, safer and more cost effective than pharmacotherapy or nontreatmnet of insomnia”.

The American Academy of Sleep Medicine

The American Academy of Sleep Medicine supports CBTi as an effective long-term treatment for insomnia in a meta-analysis published in 2006.